These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
427 related articles for article (PubMed ID: 27853163)
1. Long-term (52-week) safety and efficacy of Sacubitril/valsartan in Asian patients with hypertension. Supasyndh O; Sun N; Kario K; Hafeez K; Zhang J Hypertens Res; 2017 May; 40(5):472-476. PubMed ID: 27853163 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Sacubitril/Valsartan (LCZ696) Compared With Olmesartan in Elderly Asian Patients (≥65 Years) With Systolic Hypertension. Supasyndh O; Wang J; Hafeez K; Zhang Y; Zhang J; Rakugi H Am J Hypertens; 2017 Nov; 30(12):1163-1169. PubMed ID: 28992296 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Sacubitril/Valsartan in Chronic Type B Aortic Dissection Combined With Mild Hypertension. Wang X; Song F; Jiang L; Huang Z; Luo S; Li X; He X Am J Hypertens; 2024 Jul; 37(8):612-620. PubMed ID: 38564196 [TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction. Ito S; Satoh M; Tamaki Y; Gotou H; Charney A; Okino N; Akahori M; Zhang J Hypertens Res; 2015 Apr; 38(4):269-75. PubMed ID: 25693859 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of sacubitril/valsartan compared with olmesartan in Asian patients with essential hypertension: A randomized, double-blind, 8-week study. Huo Y; Li W; Webb R; Zhao L; Wang Q; Guo W J Clin Hypertens (Greenwich); 2019 Jan; 21(1):67-76. PubMed ID: 30536595 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of sacubitril/valsartan (LCZ696) add-on to amlodipine in Asian patients with systolic hypertension uncontrolled with amlodipine monotherapy. Wang JG; Yukisada K; Sibulo A; Hafeez K; Jia Y; Zhang J J Hypertens; 2017 Apr; 35(4):877-885. PubMed ID: 28030431 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Crystalline Valsartan/Sacubitril (LCZ696) Compared With Placebo and Combinations of Free Valsartan and Sacubitril in Patients With Systolic Hypertension: The RATIO Study. Izzo JL; Zappe DH; Jia Y; Hafeez K; Zhang J J Cardiovasc Pharmacol; 2017 Jun; 69(6):374-381. PubMed ID: 28338503 [TBL] [Abstract][Full Text] [Related]
8. Antihypertensive effect of sacubitril/valsartan: a meta-analysis. De Vecchis R; Ariano C; Soreca S Minerva Cardioangiol; 2019 Jun; 67(3):214-222. PubMed ID: 30895762 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety Comparative of Sacubitril/Valsartan vs. Olmesartan in the Treatment of hypertension: A Meta-analysis of RCTs. Han Y; Zhou Y; Na J; Li F; Sun Y Am J Hypertens; 2023 Nov; 36(12):643-650. PubMed ID: 37596996 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study. Kario K; Sun N; Chiang FT; Supasyndh O; Baek SH; Inubushi-Molessa A; Zhang Y; Gotou H; Lefkowitz M; Zhang J Hypertension; 2014 Apr; 63(4):698-705. PubMed ID: 24446062 [TBL] [Abstract][Full Text] [Related]
11. Different Doses of Sacubitril/Valsartan Compared with Olmesartan in Patients with Essential Hypertension: A Systematic Review and Meta-Analysis. Almarjan AI; Almarjan SA; Masoud AT High Blood Press Cardiovasc Prev; 2023 May; 30(3):207-218. PubMed ID: 37017901 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study. Rakugi H; Kario K; Yamaguchi M; Sasajima T; Gotou H; Zhang J Hypertens Res; 2022 May; 45(5):824-833. PubMed ID: 35058583 [TBL] [Abstract][Full Text] [Related]
13. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280 [TBL] [Abstract][Full Text] [Related]
14. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Poldermans D; Glazes R; Kargiannis S; Wernsing M; Kaczor J; Chiang YT; Yen J; Gamboa R; Fomina I Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of sacubitril/valsartan in patients with essential hypertension uncontrolled by olmesartan: A randomized, double-blind, 8-week study. Cheung DG; Aizenberg D; Gorbunov V; Hafeez K; Chen CW; Zhang J J Clin Hypertens (Greenwich); 2018 Jan; 20(1):150-158. PubMed ID: 29338113 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of 30-mg fimasartan for the treatment of patients with mild to moderate hypertension: an 8-week, multicenter, randomized, double-blind, phase III clinical study. Youn JC; Ihm SH; Bae JH; Park SM; Jeon DW; Jung BC; Park TH; Lee NH; Song JM; Yoon YW; Shin ES; Sung KC; Jung IH; Pyun WB; Joo SJ; Park WJ; Shin JH; Kang SM Clin Ther; 2014 Oct; 36(10):1412-21. PubMed ID: 25092393 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of sacubitril/valsartan in the treatment of middle-aged and elderly patients with hypertension: a systematic review and meta-analysis of randomized controlled trials. Wu HX; Liu KK; Li BN; Liu S; Jin JC Ann Palliat Med; 2022 May; 11(5):1811-1825. PubMed ID: 35672897 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of LCZ696 for Short-term Management of Essential Hypertension Compared With ARBs: A Meta-analysis of Randomized Controlled Trials. Yang S; Zhang H; Yang P; Wang C; Wu Q J Cardiovasc Pharmacol; 2021 May; 77(5):650-659. PubMed ID: 33951700 [TBL] [Abstract][Full Text] [Related]
19. Combination therapy with amlodipine/valsartan in essential hypertension: a 52-week, randomised, open-label, extension study. Smith TR; Glazer RD; Koren MJ; Wernsing M; Zhang Y Int J Clin Pract; 2010 Sep; 64(10):1367-74. PubMed ID: 20716145 [TBL] [Abstract][Full Text] [Related]
20. Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Pool JL; Glazer R; Weinberger M; Alvarado R; Huang J; Graff A Clin Ther; 2007 Jan; 29(1):61-73. PubMed ID: 17379047 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]